Soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells

Molecular and Cellular Neuroscience

Volumn 21, Issue 4, 2002, Pages 602-615

  Valerio, Alessandra ^a   Ferrario, Marina ^a   Dreano, Michel ^b   Garotta, Gianni ^b   Spano, Pierfranco ^a   Pizzi, Marina ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; BROXURIDINE; FLUORESCENT DYE; GLYCOPROTEIN GP 130; HYBRID PROTEIN; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MITOCHONDRIAL ENZYME; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION;

ANIMALIA; JANUS;

EID: 0036942881     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcne.2002.1208     Document Type: Article

References (59)

1. Agresti, C., Aloisi, F., and Levi, G. (1991). Heterotypic and homotypic cellular interactions influencing the growth and differentiation of bipotential oligodendrocyte-type-2 astrocyte progenitors in culture. Dev. Biol. 144: 16-29.
2. Agresti, C., D'Urso, D., and Levi, G. (1996). Reversible inhibitory effects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur. J. Neurosci. 8: 1106-1116.
3. Barres, B. A., Schmid, R., Sendnter, M., and Raff, M. C. (1993). Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118: 283-295.
4. Barry, C., Pearson, C., and Barbarese, E. (1996). Morphological organization of oligodendrocyte processes during development in culture and in vivo. Dev. Neurosci. 18: 233-242.
5. Bazan, J. F. (1990). Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87: 6934-6938.
6. Bazan, J. F. (1991). Neuropoietic cytokines in the hematopoietic fold. Neuron 7: 197-208.
7. Bensadoun, J. C., de Almeida, L. P., Dreano, M., Aebischer, P., and Deglon, N. (2001). Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. Eur. J. Neurosci. 14: 1753-1761.
8. Bögler, O., Wren, D., Barnett, S. C., Land, H., and Noble, M. (1990).Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc. Natl. Acad. Sci. USA 87: 6368-6372.
9. Buttke, T. M., McCubrey, J. A., and Owen, T. C. (1993). Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods 157: 233-240.
10. Calzà, L., Fernandez, M., Giuliani, A., Aloe, L., and Giardino, L. (2002). Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA 99: 3258-3263.
11. Cattaneo, E., Conti, L., and De-Fraja, C. (1999). Signalling through the JAK-STAT pathway in the developing brain. Trends Neurosci. 22: 365-369.
12. Chang, A., Tourtellotte, W. W., Rudick, R., and Trapp, B. D. (2002). Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346: 165-173.
13. Chebath, J., Fischer, D., Kumar, A., Oh, J. W., Kolett, O., Lapidot, T., Fischer, M., Rose-John, S., Nagler, A., Slavin, S., and Revel, M. (1997). Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. Eur. Cytokine Netw. 8: 359-365.
14. Dell'Albani, P., Kahn, M. A., Cole, R., Condorelli, D. F., Giuffrida-Stella, A. M., and de Vellis, J. (1998). Oligodendroglial survival factors, PDGF-AA and CNTF, activate similar JAK/STAT signaling pathways. J. Neurosci. Res. 54: 191-205.
15. Diab, A., Zhu, J., Xiao, B. G., Mustafa, M., and Link, H. (1997). High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J. Neuropathol. Exp. Neurol. 56: 641-650.
16. Di Marco, R., Khademi, M., Wallstrom, E., Iacobaeus, E., Salvaggio, A., Caracappa, S., Papoian, R., Nicoletti, F., and Olsson, T. (2001). Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 116: 168-177.
17. Elson, G. C., Lelievre, E., Guillet, C., Chevalier, S., Plun-Favreau, H., Froger, J., Suard, I., de Coignac, A. B., Delneste, Y., Bonnefoy, J. Y., Gauchat, J. F., and Gascan, H. (2000). CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 3: 867-872.
18. Eugster, H. P., Frei, K., Kopf, M., Lassmann, H., and Fontana, A. (1998). IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 28: 2178-2187.
19. Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J. P., Kallen, K. J., Wollmer, A., Grotzinger, J., and Rose-John, S. I. (1997). A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15: 142-145.
20. Fisher, J., Mizrahi, T., Schori, H., Yoles, E., Levkovitch-Verbin, H., Haggiag, S., Revel, M., and Schwartz, M. (2001). Increased posttraumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility. J. Neuroimmunol. 119: 1-9.
21. Frei, K., Fredrikson, S., Fontana, A., and Link, H. (1991). Interleukin-6 is elevated in plasma in multiple sclerosis. J. Neuroimmunol. 31: 147-153.
22. Gard, A. L., Williams, W. C., II, and Burrell, M. R. (1995). Oligodendroblasts distinguished from O-2A glial progenitors by surface phenotype (O4+GalC-) and response to cytokines using signal transducer LIFR beta. Dev. Biol. 167: 596-608.
23. Haggiag, S., Chebath, J., and Revel, M. (1999). Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor-interleukin-6 chimera. FEBS Lett. 457: 200-204.
24. Haggiag, S., Zhang, P. L., Slutzky, G., Shinder, V., Kumar, A., Chebath, J., and Revel, M. (2001). Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin-6 receptor-interleukin-6 chimera. J. Neurosci. Res. 64: 564-574.
25. Hautecoeur, P., Forzy, G., Gallois, P., Demirbilek, V., and Feugas, O. (1997). Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol. Belg. 97: 240-243.
26. Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334: 297-314.
27. Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., and Rose-John, S. (2001). Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268: 160-167.
28. Kahn, M. A., and De Vellis, J. (1994). Regulation of an oligodendrocyte progenitor cell line by the interleukin-6 family of cytokines. Glia 12: 87-98.
29. Kamaraju, A. K., Bertolotto, C., Chebath, J., and Revel, M. (2002). Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. J. Biol. Chem. 277: 15132-15141.
30. Kirischuk, S., Neuhaus, J., Verkhratsky, A., and Kettenmann, H. (1995). Preferential localization of active mitochondria in process tips of immature retinal oligodendrocytes. Neuroreport 6: 737-741.
31. Kollet, O., Aviram, R., Chebath, J., Ben-Hur, H., Nagler, A., Shultz, L., Revel, M., and Lapidot, T. (1999). The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice. Blood 94: 923-931.
32. Levi, G., Aloisi, F., and Wilkin, G. P. (1987). Differentiation of cerebellar bipotential glial precursors into oligodendrocytes in primary culture: Developmental profile of surface antigens and mitotic activity. J. Neurosci. Res. 18: 407-417.
33. Levine, J. M., Reynolds, R., and Fawcett, J. W. (2001). The oligodendrocyte precursor cell in health and disease. Trends Neurosci. 24: 39-47.
34. Lillien, L. E., Sendtner, M., and Raff, M. C. (1990). Extracellular matrix-associated molecules collaborate with ciliary neurotrophic factor to induce type-2 astrocyte development. J. Cell Biol. 111: 635-644.
35. Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., Klonowski, P., Austin, A., Lad, N., Kaminski, N., Galli, S. J., Oksenberg, J. R., Raine, C. S., Heller, R., and Steinman, L. (2002). Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Medicine 8: 500-508.
36. Louis, J. C., Magal, E., Takayama, S., and Varon, S. (1993) CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 259: 689-692.
37. Maimone, D., Guazzi, G. C., and Annunziata, P. (1997). IL-6 detection in multiple sclerosis brain. J. Neurol. Sci. 146: 59-65.
38. Marmur, R., Kessler, J. A., Zhu, G., Gokhan, S., and Mehler, M. F. (1998). Differentiation of oligodendroglial progenitors derived from cortical multipotent cells requires extrinsic signals including activation of gp130/LIFbeta receptors. J. Neurosci. 18: 9800-9811.
39. März, P., Heese, K., Hock, C., Golombowski, S., Müller-Spahn, F., Rose-John, S., and Otten, U. (1997). Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 239: 29-32.
40. März, P., Otten, U., and Rose-John, S. (1999). Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur. J. Neurosci. 11: 2995-3004.
41. Matsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., and Akira, S. (1993) Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. USA 90: 10193-10197.
42. Mayer, M., Bhakoo, K., and Noble, M. (1994). Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 120: 143-153.
43. Mendel, I., Katz, A., Kozak, N., Ben-Nun, A., and Revel, M. (1998). Interleukin-6 functions in autoimmune encephalomyelitis: A study in gene-targeted mice. Eur. J. Immunol. 28: 1727-1737.
44. Nait-Oumesmar, B., Decker, L., Lachapelle, F., Avellana-Adalid, V., Bachelin, C., and Van Evercooren, A. B. (1999). Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination. Eur. J. Neurosci. 11: 4357-4366.
45. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G. D., Taga, T., and Kishimoto, T. (1993). Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126.
46. Okuda, Y., Sakoda, S., Bernard, C. C., Fujimura, H., Saeki, Y., Kishimoto, T., and Yanagihara, T. (1998). IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10: 703-708.
47. Okuda, Y., Sakoda, S., Fujimura, H., Saeki, Y., Kishimoto, T., and Yanagihara, T. (1999). IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 101(2): 188-196.
48. Raff, M. C., Miller, R. H., and Noble, M. (1983). A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303: 390-396.
49. Richter-Landsberg, C. (2001). Organization and functional roles of the cytoskeleton in oligodendrocytes. Microsc. Res. Tech. 52: 628-636.
50. Rodriguez, M., Pavelko, K. D., McKinney, C. W., and Leibowitz, J. L. (1994). Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J. Immunol. 153: 3811-3821.
51. Rose-John, S., and Heinrich, P. C. (1994). Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem. J. 300: 281-290.
52. Samoilova, E. B., Horton, J. L., Hilliard, B., Liu, T. S., and Chen, Y. (1998). IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161: 6480-6486.
53. Sawada, M., Itoh, Y., Suzumura, A., and Marunouchi, T. (1993). Expression of cytokine receptors in cultured neuronal and glial cells. Neurosci. Lett. 160: 131-134.
54. Simpson, P. B., Mehotra, S., Lange, G. D., and Russell, J. T. (1997). High density distribution of endoplasmic reticulum proteins and mitochondria at specialized Ca2+ release sites in oligodendrocyte processes. J. Biol. Chem. 272: 22654-22661.
55. Smith, J., Ladi, E., Mayer-Proschel, M., and Noble, M. (2000). Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc. Natl. Acad. Sci. USA 97: 10032-10037.
56. Taga, T., and Kishimoto, T. (1997). Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15: 797-819.
57. Tang, D. G., Tokumoto, Y. M., and Raff, M. C. (2000). Long-term culture of purified postnatal oligodendrocyte precursor cells. Evidence for an intrinsic maturation program that plays out over months. J. Cell Biol. 148: 971-984.
58. Vos, J. P., Gard, A. L., and Pfeiffer, S. E. (1996). Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. Perspect Dev. Neurobiol. 4: 39-52.
59. Willenborg, D. O., Fordham, S. A., Cowden, W. B., and Ramshaw, I. A. (1995). Cytokines and murine autoimmune encephalomyelitis: Inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand. J. Immunol. 41: 31-41.